Cargando…

Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support

PURPOSE: We present the case of a 56-year-old man with stage IV sarcoidosis on veno-venous extracorporeal membrane oxygenation (VV-ECMO) support for the management of respiratory failure receiving treatment with isavuconazole for invasive aspergillosis. SUMMARY: VV-ECMO is an increasingly utilized l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Michelle, Kludjian, Geena, Mohrien, Kerry, Morita, Kazumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305536/ https://www.ncbi.nlm.nih.gov/pubmed/35377411 http://dx.doi.org/10.1093/ajhp/zxac043

Ejemplares similares

Trough Concentrations of Vancomycin in Patients Undergoing Extracorporeal Membrane Oxygenation
por: Park, So Jin, et al.
Publicado: (2015)

Variability of Isavuconazole Trough Concentrations during Longitudinal Therapeutic Drug Monitoring
por: Bolcato, Léa, et al.
Publicado: (2022)

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
por: Donnelley, Monica A, et al.
Publicado: (2016)

The impact of extracorporeal membrane oxygenation on the exposure to isavuconazole: a plea for thorough pharmacokinetic evaluation
por: Mertens, Beatrijs, et al.
Publicado: (2022)

611. Increased isavuconazole loading dosage yields earlier attainment of serum target concentrations in critical ill patients with extracorporeal membrane oxygenation
por: Hatzl, Stefan, et al.
Publicado: (2023)

Remission of hepatotoxicity in chronic pulmonary aspergillosis patients after lowering trough concentration of voriconazole
por: Teng, Guo-Jie, et al.
Publicado: (2020)

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
por: Desai, Amit V., et al.
Publicado: (2017)

Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
por: Jenks, Jeffrey D, et al.
Publicado: (2018)

Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Isavuconazole: Case Report and Review of the Literature
por: Jacobs, Samantha E., et al.
Publicado: (2017)

Invasive pulmonary aspergillosis is associated with adverse clinical outcomes in critically ill patients receiving veno-venous extracorporeal membrane oxygenation
por: Rodriguez-Goncer, I., et al.
Publicado: (2018)

Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review
por: Mertens, Beatrijs, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
por: Harrington, Rachel, et al.
Publicado: (2016)

Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations
por: Natesan, Suganthini Krishnan, et al.
Publicado: (2016)

Outcomes of Fungemia in Patients Receiving Extracorporeal Membrane Oxygenation
por: Rosas, Melissa M, et al.
Publicado: (2022)

Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden
por: Floros, Lefteris, et al.
Publicado: (2019)

The pharmacokinetic challenge of treating invasive aspergillosis complicating severe influenzae assisted by extracorporeal membrane oxygenation
por: Winiszewski, Hadrien, et al.
Publicado: (2018)

Successful long-term extracorporeal membrane oxygenation for invasive pulmonary aspergillosis: a case report
por: Tanaka, Hiroyuki, et al.
Publicado: (2017)

Plasma Peak and Trough Gentamicin Concentrations in Hospitalized Horses Receiving Intravenously Administered Gentamicin
por: Bauquier, J.R., et al.
Publicado: (2015)

Pharmacokinetics of Teicoplanin in a Patient with Coronavirus Disease 2019 Receiving Veno-venous Extracorporeal Membrane Oxygenation
por: Hirayu, Nobuhisa, et al.
Publicado: (2022)

Variation in electroencephalography and neuroimaging for children receiving extracorporeal membrane oxygenation
por: Kohne, Joseph G., et al.
Publicado: (2023)

Predictors of circuit health in neonatal patients receiving extracorporeal membrane oxygenation (ECMO)
por: Hazboun, Rita G., et al.
Publicado: (2022)

Lipoprotein concentration in patients requiring extracorporeal membrane oxygenation
por: Tanaka, Sébastien, et al.
Publicado: (2021)

COVID-19 Associated Pulmonary Aspergillosis in Patients on Extracorporeal Membrane Oxygenation Treatment—A Retrospective Study
por: Nuh, Ali, et al.
Publicado: (2023)

Trough Concentrations of Specific Antibodies in Primary Immunodeficiency Patients Receiving Intravenous Immunoglobulin Replacement Therapy
por: Hassin, Ori, et al.
Publicado: (2021)

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates
por: Garcia, Brandon, et al.
Publicado: (2022)

Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019
por: Ide, Satoshi, et al.
Publicado: (2021)

Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations
por: Zurl, Christoph, et al.
Publicado: (2020)

Issues in the management of invasive pulmonary aspergillosis in non-neutropenic patients in the intensive care unit: A role for isavuconazole
por: Bassetti, Matteo, et al.
Publicado: (2018)

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
por: Andes, David R., et al.
Publicado: (2018)

358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)
por: Cheng, Matthew P, et al.
Publicado: (2018)

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial
por: Perfect, John R., et al.
Publicado: (2018)

Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease
por: Lee, Annie, et al.
Publicado: (2019)

Successful Multimodal Therapy with Intracerebral Liposomal Amphotericin B and Systemic High-Dose Isavuconazole in Proven Disseminated Aspergillosis
por: Feys, Simon, et al.
Publicado: (2023)

Phenotypes of severe COVID-19 ARDS receiving extracorporeal membrane oxygenation
por: Zhang, Joe, et al.
Publicado: (2021)

Prevalence and Impact of Lupus Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation
por: Kornfehl, Andrea, et al.
Publicado: (2023)

Isavuconazole as salvage therapy for mucormycosis
por: Graves, Bianca, et al.
Publicado: (2016)

The effect of inflammation on voriconazole trough concentrations in children
por: ter Avest, Mendy, et al.
Publicado: (2016)

360. Breakthrough Invasive Pulmonary Aspergillosis During Isavuconazole Prophylaxis in Patients with Hematologic Malignancies: A Single-Center Experience
por: Fontana, Lauren, et al.
Publicado: (2018)

Publisher Correction: Predictors of circuit health in neonatal patients receiving extracorporeal membrane oxygenation (ECMO)
por: Hazboun, Rita G., et al.
Publicado: (2022)

Population pharmacokinetics of remifentanil in critically ill patients receiving extracorporeal membrane oxygenation
por: Yang, Seungwon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6d4hvpqm0uv0birrmk5dnes7fv